Feb. 21, 2019

Reducing the Risk of Heart Attack, Stroke, and Leg Amputation

Until the advent of the COMPASS trial, secondary prevention in patients with peripheral artery disease consisted of either aspirin or clopidogrel monotherapy. Now, by adding a low-dose DOAC to low-dose aspirin, medical therapy may reduce the need for major vascular surgery or endovascular procedures.

Join expert faculty live on April 4 to learn about the latest evidence, indications, and guideline-based utilization of dual antiplatelet therapy.

Thursday, April 4, 2019

12–1pm ET | 9–10am PT
Earn up to 1.00 AMA PRA Category 1 Credit™ of continuing education

Share this page